Related Experiment Video
Updated: Jun 17, 2026
08:56
Development of New Therapeutic Applications Using Microfluidics
Published on: October 1, 2007
Diabodies: molecular engineering and therapeutic applications
1Department of Biologics of the Abbott Bioresearch Center, Worcester, Massachusetts 01545, USA. chengbin.wu@abbott.com
Drug News & Perspectives
|December 18, 2009
Summary
Bispecific antibodies, like diabodies, redirect immune cells to kill cancer cells. Despite manufacturing challenges, these engineered molecules show promise for cancer therapy development.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Bispecific antibodies offer targeted cancer treatment by engaging effector cells against tumor cells.
- Diabodies are a key class of engineered bispecific antibodies developed over two decades for tumor targeting.
Purpose of the Study:
- To review the development and therapeutic potential of diabodies in cancer treatment.
- To highlight the renewed interest in bispecific antibody formats for cancer therapy.
Main Methods:
- Review of bispecific antibody formats, focusing on diabodies.
- Analysis of optimization efforts for physicochemical and functional properties.
- Examination of in vivo antitumor efficacy studies.
Main Results:
- Diabodies have demonstrated tumor-targeting capabilities and antitumor efficacy in preclinical models.
- Recent advancements have introduced novel bispecific formats.
- T-cell-retargeting mechanisms are gaining clinical validation.
Conclusions:
- Diabodies and their derivatives are promising therapeutic strategies for cancer.
- Further development is needed to address manufacturing yields and drug-like properties.
- Continued research into bispecific antibodies is warranted for cancer therapy.
